]>
IRCT2017080135444N1 IRCT 2017-11-06 Vice chancellor for research, Tehran University of Medical Sciences The effect of nanocurcumin and ubiquinone in migraine treatment The combined effects of nanocurcumin and ubiquinone supplementation on serum levels of homocysteine, calcitonin gene-related peptide, oxidative stress index, gene expression and activity of some antioxidant enzymes in migraine patients: Randomized double blind placebo controlled trial 2017-09-23 anticipated 80 Complete https://irct.ir/trial/26783 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention. 2-3 Migraine without aura. Patients will be divided into four groups, according to stratified randomization method: 1.The group receiving ubiquinone (sauna medicine in Parseh, Iran) (100 mg three times daily) and nanocorcomin (Sina Kurkamin, Iran) (80 mg per day). 2.Nano-curcumin supplement and ubiquinone placebo (Minoo Co., Iran). 3.ubiquinone Supplement and Curcumin Placebo (Minoo Co., Iran). 4.The control group consisted of patients receiving ubiquinone placebo and curcumin placebo for two months..
public Mohammad Prohan
No. 44, Hojjat Doust Alley, Naderi ave, Keshavarz Blvd, Tehran.
Tehran Iran (Islamic Republic of) +98 21 8895 5975 prohan-m@razi.tums.ac.ir Tehran University of Medical Sciences scientific Mohammad Prohan
No. 44, Hojjat Doust Alley, Naderi ave, Keshavarz Blvd, Tehran.
Tehran Iran (Islamic Republic of) +98 21 8895 5975 prohan-m@razi.tums.ac.ir Tehran University of Medical Sciences and Health Services Iran (Islamic Republic of) Inclusion criteria: 20 to 45 years old; Patients with episodic migraine; Migraine Diagnosis by International Headache Society Criteria as Applied by a Neurologist; No nutritional supplement or professional sports activities four weeks before intervention; People who are willing to cooperate voluntarily. Exclusion criteria: Kidney disease; liver disease; pancreatitis; diabetes; cancer; thyroid disorders and inflammatory diseases based on medical history; Malnutrition (body mass index less than 18.5) and obesity (body mass index greater than 30); Vitamin supplementation during the three months before intervention; Pregnancy; Alcohol consumption over the past six months; smoking; Patients with history of cardiovascular disease; Taking anti-inflammatory drugs or supplements such as ubiquinone and curcumin; Allergic reaction to the ubiquinone and/or Curcumin supplement; Lack of patient collaboration; Any significant changes in diet and routine life. 20 years 45 years Both G43.0 Migraine without aura [common migraine] Treatment - Drugs Patients will be divided into four groups, according to stratified randomization method: 1.The group receiving ubiquinone (sauna medicine in Parseh, Iran) (100 mg three times daily) and nanocorcomin (Sina Kurkamin, Iran) (80 mg per day). 2.Nano-curcumin supplement and ubiquinone placebo (Minoo Co., Iran). 3.ubiquinone Supplement and Curcumin Placebo (Minoo Co., Iran). 4.The control group consisted of patients receiving ubiquinone placebo and curcumin placebo for two months. Number of headache attacks. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Questionnaires to assess disease progression. Duration of the headache. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Questionnaires to assess disease progression. Headache severity. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Questionnaires to assess disease progression. Serum level of calcitonin gene-related peptide. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Using appropriate laboratory methods for each variable. Serum levels of homocysteine. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Using appropriate laboratory methods for each variable. Oxidative stress profile. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Using appropriate laboratory methods for each variable. Activity of antioxidant enzymes catalase, superoxide dismutase, glutathione peroxidase. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Using appropriate laboratory methods for each variable. Gene expression of anti-oxidant enzymes catalase, superoxide dismutase, glutathione peroxidase in peripheral blood mononuclear cells. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Using appropriate laboratory methods for each variable. Vice chancellor for research, Tehran University of Medical Sciences Approved 2017-08-01 Ethics Committee of Tehran University of Medical Sciences No. 44, Hojjat Doust Alley, Naderi ave, Keshavarz Blvd, Tehran. Tehran Iran (Islamic Republic of)